학술논문
Phase I dose escalation and expansion study of golidocitinib, a highly selective JAK1 inhibitor, in relapsed or refractory peripheral T-cell lymphomas
Document Type
Article
Author
Source
In Annals of Oncology November 2023 34(11):1055-1063
Subject
Language
ISSN
0923-7534